Amgen (AMGN) says late-stage testing of its Aranesp drug candidate failed to meet its primary...

|About: Amgen Inc. (AMGN)|By:, SA News Editor

Amgen (AMGN) says late-stage testing of its Aranesp drug candidate failed to meet its primary endpoint of reducing deaths in heart-failure patients. The six-year trial worked with nearly 2,300 patients with symptomatic systolic heart failure and anemia by attempting to treat their anemia caused by kidney dialysis.